Version July 2025
| Denosumab | Bisphosphonates | |
| Route of administration | Subcutaneous | Intravenous |
| Osteonecrosis of the jaw | X | X |
| Hypocalcemia | X | X |
| Nephrotoxicity | X | |
| Atypical femoral fractures | X | X |
| Renal elimination/need for dose adjustment in renal insufficiency | X | |
| Flu-like symptoms (acute-phase reaction) | X | |
| Bone, joint, muscle pain | X |
